Common use of Celgene’s Right to Sublicense Clause in Contracts

Celgene’s Right to Sublicense. (a) In the United States. ENTREMED hereby grants to CELGENE the right to sublicense ENTREMED INTELLECTUAL PROPERTY in the United States with the consent of ENTREMED, to be exercised in ENTREMED's sole discretion. (b) Outside the United States. ENTREMED hereby grants to CELGENE the right to sublicense ENTREMED INTELLECTUAL PROPERTY outside the United States with the written consent of ENTREMED, which consent shall not be unreasonably withheld. Outside the United States, CELGENE shall use reasonable efforts to negotiate sublicensing agreements that are commercially reasonable according to contemporaneous prevailing standards within the pharmaceutical industry.